CHINARES PHARMA's stock price plummeted 5.02% during intraday trading on Monday, following the release of weak financial results from its subsidiary.

The sharp decline came after China Resources Pharmaceutical, the parent company, filed a disclosure showing that its subsidiary China Resources Double-Crane Pharmaceutical reported a year-on-year decrease in both profit and revenue for the first quarter of 2026.

According to the filing, the subsidiary's net profit fell to 501.4 million yuan from 522.7 million yuan a year earlier, while revenue declined to 2.81 billion yuan from 3.08 billion yuan in the prior year period, indicating weaker operational performance.